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Letters to the Editor
Figure 1 MboII restriction site on human MTHFR (GenBank
accession U09806). MboII recognizes GAAGA (upper nucleotide se-
quence). MTHFR 1298C (lower sequence) abolishes the MboII site.
Sequence data were obtained from GenBank (accession number
U09806). The lower sequence is identical to the GenBank sequence.
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The 1298(ArC) Mutation of
Methylenetetrahydrofolate Reductase Should Be
Designated to the 1289 Position of the Gene
To the Editor:
van der Put et al. (1998) recently reported that a second
commonmutation within the gene coding for the enzyme
methylenetetrahydrofolate reductase (MTHFR; E.C.
1.5.1.20) results in significantly reduced catalytic activ-
ity. This mutation is important because MTHFR plays
a significant role in the metabolism of folate and, ulti-
mately, of homocysteine, which is implicated as a risk
factor for neural-tube defects (Copp et al. 1990). van
der Put et al. (1998) designated this mutation—MTHFR
1298(ArC)—as changing a glutamate into an alanine
residue. A review of the human MTHFR mRNA se-
quence (GenBank accession number U09806) shows that
this mutation is not present in the human sequence at
position 1298 but may, in fact, be mutation 1289(ArC).
There are two reasons why this may be so. First, the
nucleotide at 1298 is a T (fig. 1). Second, the authors
report that this mutation, 1298C, destroys an MboII
restriction site. The recognition site for MboII is GAA-
GANNNNNNN/N/. There is no MboII restriction site
at 1298; however, there is one at 1289 in the human
MTHFR sequence (fig. 1). The enzymeMboII is expected
to cut between nucleotides 1297 and 1298, whereas the
mutation they describe is likely to be at position 1289.
Although this does not affect the results of their study,
it is important to accurately designate mutations to the
proper nucleotide position, thereby avoiding errors in
subsequent research concerning this important gene.
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Reply to Donnelly
To the Editor:
Donnelly comments, in his letter, on the confusing num-
bering used for the nomenclature of the second single-
